Search results for "RANKL"

showing 10 items of 46 documents

Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases.

2011

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPhysiologyClinical Biochemistrycolorectal cancerBone NeoplasmsBone remodelingMetastasisProstate cancerbreast cancerOsteoprotegerinInternal medicinemedicineHumansbone metastasibiologyReceptor Activator of Nuclear Factor-kappa Bbusiness.industryMedicine (all)Bone metastasisCell Biologymedicine.diseasePrimary tumorbone metastasis; breast cancer; colorectal cancerImmunohistochemistryEndocrinologyBone Neoplasms; Humans; Immunohistochemistry; Receptor Activator of Nuclear Factor-kappa B; Medicine (all); Physiology; Clinical Biochemistry; Cell BiologyRANKLCancer researchbiology.proteinImmunohistochemistrybusinessJournal of cellular physiology
researchProduct

Progestogens and risk of breast cancer: a link between bone and breast?

2015

This article reviews the data supporting the role of receptor activator of the nuclear factor kappa (RANK) and its ligand, RANKL, in progestogen-induced breast cancer. Both experimental and clinical studies have been included. The expression of both RANK and RANKL has been described in epithelial cells of both mice and humans. Experiments of gain and loss of function in mice have shown that RANK/RANKL mediate alveologenesis during pregnancy or the estrous cycle. Moreover, the participation of the RANK/RANKL has been detected in models of breast carcinogenesis associated with progestogens-like medroxyprogesterone acetate. Recent clinical studies have found that the expression of RANK is asso…

musculoskeletal diseases0301 basic medicineEndocrinology Diabetes and MetabolismOsteoclastsBone NeoplasmsBreast NeoplasmsMice03 medical and health sciences0302 clinical medicineEndocrinologyBreast cancerRisk FactorsmedicineAnimalsHumansMedroxyprogesterone acetateBreastReceptorProgesteroneLoss functionEstrous cyclePregnancyReceptor Activator of Nuclear Factor-kappa BbiologyActivator (genetics)business.industryRANK LigandObstetrics and Gynecologymedicine.disease030104 developmental biologyRANKL030220 oncology & carcinogenesisImmunologybiology.proteinCancer researchFemaleProgestinsbusinessmedicine.drugGynecological Endocrinology
researchProduct

The role of osteoprotegerin in the crosstalk between vessels and bone: Its potential utility as a marker of cardiometabolic diseases

2018

International audience; Among the numerous molecules that are being studied for their potential utility as biomarkers of cardiovascular diseases, much interest has been shown in the superfamily of tumor necrosis factor (TNF) receptors. Members of this family include osteoprotegerin (OPG) and its ligands, which are receptor activators of nuclear factor κB ligand (RANKL) and TNF-related apoptosis-inducing ligand (TRAIL). These signals may be expressed and regulated, and their functions could be involved in several physiological and pathological processes. The relationship between bone regulatory proteins and vascular biology has attracted attention, and it has been suggested that OPG may medi…

musculoskeletal diseases0301 basic medicinemedicine.medical_specialtyOsteoporosisInflammationDisease030204 cardiovascular system & hematologyBone remodeling03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemOsteoprotegerinInternal medicinemedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacology (medical)Vascular CalcificationReceptorPharmacologybiologyChemistryOsteoprotegerinmedicine.disease3. Good health030104 developmental biologyEndocrinologyCardiovascular DiseasesRANKLbiology.proteinTumor necrosis factor alphaBone Remodelingmedicine.symptomPharmacology & Therapeutics
researchProduct

An approach to a biomimetic bone scaffold: increased expression of BMP-2 and of osteoprotegerin in SaOS-2 cells grown onto silica-biologized 3D print…

2012

Three-dimensional printed (3D printed) bone material is needed to close the shortage and to avoid the potential health risks associated with autografts and allografts, in the treatment of bone fractures/nonunions or bone trauma. Here we describe the fabrication of 3D printed scaffold, initially prepared form Ca-sulfate that has been impregnated/biologized with Ca-phosphate or with silica. The 3D printed grids had a size mesh of 200 μm; the chemical composition was determined by energy dispersive X-ray spectroscopy or conventional chemical analysis. Using human SaOS-2 cells (human osteogenic cells) it is shown that both the Ca-sulfate, and the Ca-phosphate or the silica impregnated Ca-sulfat…

musculoskeletal diseases0303 health sciencesScaffoldbiologyChemistryGeneral Chemical Engineering02 engineering and technologyGeneral Chemistry021001 nanoscience & nanotechnologyBone morphogenetic protein 2In vitro03 medical and health sciencesmedicine.anatomical_structureOsteoprotegerinOsteoclastIn vivoRANKLmedicinebiology.proteinBiophysics0210 nano-technologySaos-2 cells030304 developmental biologyRSC Adv.
researchProduct

Estudio clínico, radiográfico y plasmático de la osteonecrosis de los maxilares por bisfosfonatos en un grupo de183 pacientes

2016

Osteonecrosis of the jaw is a particular form of chronic osteomyelitis caused by bisphosphonates (BF) or by other pharmacological or anti-angiogenic drugs. The BF are potent drugs inhibitors of osteoclasts by exerting a strong interaction with these cells, producing a sharp decrease of bone resorption. Objectives: To analyse clinical and radiologic characteristics as well as differences in the plasma levels of the Activation Nuclear Kappa receptor ligand (RANKL) and of osteoprotegerin (OPG) in a group of patients with osteonecrosis and compared to healthy controls. In addition, within the Group of patients with osteonecrosis maxillary study if there is relationship between plasma levels of …

musculoskeletal diseasesBisfosfonatosRadiologíaOsteonecrosisRANKLOPGInterleuquinas
researchProduct

Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint.

2005

Abstract During embryogenesis the bone tissue of craniomandibular joint (CMJ) is formed through two pathways: intramembranous ossification and endochondral ossification. The development process is under the control of regulatory factors.The osteoprotegerin (OPG) and the receptor activator of nuclear factor (NF)-κB ligand are key regulators of osteoclastogenesis. The aim of this study is the localization of OPG and RANKL mRNA and protein in the foetal CMJ by immunohistochemistry (IHC) and in situ hybridization (ISH). The main results were: OPG and RANKL mRNA and protein were co-localized in the same cell types; OPG and RANKL were specially immunolocated in osteogenic cells; immunolabeling wa…

musculoskeletal diseasesCartilage Articularmedicine.medical_specialtyReceptors Cytoplasmic and NuclearIn situ hybridizationBiologyBone tissueReceptors Tumor Necrosis FactorBone remodelingOsteoprotegerinOsteogenesisInternal medicineBone cellmedicineHumansRNA MessengerEndochondral ossificationIn Situ HybridizationGlycoproteinsMembrane GlycoproteinsReceptor Activator of Nuclear Factor-kappa BTemporomandibular JointRANK LigandOsteoprotegerinCell BiologyGeneral MedicineImmunohistochemistryCell biologyEndocrinologymedicine.anatomical_structureRANKLIntramembranous ossificationbiology.proteinCarrier ProteinsDevelopmental BiologyTissuecell
researchProduct

Silicate modulates the cross-talk between osteoblasts (SaOS-2) and osteoclasts (RAW 264.7 cells): inhibition of osteoclast growth and differentiation

2012

It has been shown that inorganic monomeric and polymeric silica/silicate, in the presence of the biomineralization cocktail, increases the expression of osteoprotegerin (OPG) in osteogenic SaOS-2 sarcoma cells in vitro. In contrast, silicate does not affect the steady-state gene expression level of the osteoclastogenic ligand receptor activator of NF-κB ligand (RANKL). In turn it can be expected that the concentration ratio of the mediators OPG/RANKL increases in the presence of silicate. In addition, silicate enhances the growth potential of SaOS-2 cells in vitro, while it causes no effect on RAW 264.7 cells within a concentration range of 10-100 µM. Applying a co-cultivation assay system,…

musculoskeletal diseasesCell SurvivalCellular differentiationmedicine.medical_treatmentAcid PhosphataseMineralogyOsteoclastsCell Count02 engineering and technologyCell CommunicationBiochemistryCell Line03 medical and health sciencesMiceOsteoprotegerinOsteoclastOsteogenesismedicineAnimalsHumansMolecular BiologyRAW 264.7 Cells030304 developmental biologyTartrate-resistant acid phosphataseCell Proliferation0303 health sciencesOsteoblastsbiologyBone Density Conservation AgentsChemistryTartrate-Resistant Acid PhosphataseMacrophagesSilicatesRANK LigandCell DifferentiationCell Biology021001 nanoscience & nanotechnologyCoculture TechniquesCell biologyIsoenzymesmedicine.anatomical_structureCytokineCell cultureRANKLbiology.protein0210 nano-technologyJ. Cell. Biochem.
researchProduct

Osteoprotegerin: multiple partners for multiple functions.

2013

Osteoprotegerin (OPG) is an essential secreted protein in bone turnover due to its role as a decoy receptor for the Receptor Activator of Nuclear Factor-kB ligand (RANKL) in the osteoclasts, thus inhibiting their differentiation. However, there are additional ligands of OPG that confer various biological functions. OPG can promote cell survival, cell proliferation and facilitates migration by binding TNF-related apoptosis inducing ligand (TRAIL), glycosaminoglycans or proteoglycans. A large number of in vitro, pre-clinical and clinical studies provide evidences of OPG involvement in vascular, bone, immune and tumor biology. This review describes an overview of the different OPG ligands regu…

musculoskeletal diseasesCell SurvivalEndocrinology Diabetes and MetabolismImmunologyOsteoclastsGeneral Biochemistry Genetics and Molecular BiologyTNF-Related Apoptosis-Inducing LigandOsteoprotegerinImmunology and AllergyAnimalsHumansCell adhesionReceptorCell ProliferationbiologyActivator (genetics)Cell growthChemistryRANK LigandOsteoprotegerinCell DifferentiationIn vitroCell biologyBiochemistryRANKLbiology.proteinDecoyCytokinegrowth factor reviews
researchProduct

Osteogenic differentiation of periodontal fibroblasts is dependent on the strength of mechanical strain

2012

Abstract Objective During orthodontic therapy the correct strength of mechanical strain plays a key role for bone remodelling during tooth movement. Aim of this study was to investigate the osteogenic differentiation of human periodontal ligament fibroblasts (HPdLF) depending on the applied strength of mechanical strain compared to osteoblasts (HOB). Design HPdLF and HOB were loaded with different strengths (1%, 5% and 10%) of static mechanical strain (SMS) for 12 h in vitro. Viability was verified by MTT and apoptosis by TUNEL assay. Gene expression of cyclin D1, collagen type-1 (COL-I), alkaline phosphatase (ALP), osteocalcin, osteoprotegerin (OPG) and receptor activator of the NF-κB liga…

musculoskeletal diseasesCell SurvivalPeriodontal LigamentGene ExpressionDentistryApoptosisEnzyme-Linked Immunosorbent AssayReal-Time Polymerase Chain ReactionCollagen Type IBone remodelingAndrologyCyclin D1OsteoprotegerinOsteogenesisIn Situ Nick-End LabelingHumansPeriodontal fiberCyclin D1RNA MessengerGeneral DentistryCells CulturedAnalysis of VarianceOsteoblastsTUNEL assaybiologybusiness.industryChemistryRANK LigandOsteoprotegerinCell DifferentiationCell BiologyGeneral MedicineFibroblastsAlkaline PhosphataseOtorhinolaryngologyRANKLOsteocalcinbiology.proteinAlkaline phosphataseStress MechanicalbusinessArchives of Oral Biology
researchProduct

Evaluation of the osteoclastogenic process associated with RANK / RANK-L / OPG in odontogenic myxomas

2018

Background Odontogenic myxoma (OM) is a benign intraosseous neoplasm that exhibits local aggressiveness and high recurrence rates. Osteoclastogenesis is an important phenomenon in the tumor growth of maxillary neoplasms. RANK (Receptor Activator of Nuclear Factor κappa B) is the signaling receptor of RANK-L (Receptor activator of nuclear factor kappa-Β ligand) that activates the osteoclasts. OPG (osteoprotegerin) is a decoy receptor for RANK-L that inhibits pro-osteoclastogenesis. The RANK / RANKL / OPG system participates in the regulation of osteolytic activity under normal conditions, and its alteration has been associated with greater bone destruction, and also with tumor growth. Object…

musculoskeletal diseasesMaleOdontogenic myxomaRANK-LRANKOdontogenic myxoma03 medical and health sciences0302 clinical medicineOsteoprotegerinOsteoclastogenesis.MedicineNeoplasmHumansMIXOMAReceptorGeneral DentistryLanguageOSTEOGENESISDental follicleOral Medicine and PathologybiologyActivator (genetics)business.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDental follicleLIGANDO RANKOtorhinolaryngologyRANKL030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASCancer researchbiology.proteinImmunohistochemistryOPGSurgerybusinessMyxomaMedicina Oral, Patología Oral y Cirugía Bucal
researchProduct